Human germline hedgehog pathway mutations predispose to fatty liver

被引:21
|
作者
Guillen-Sacoto, Maria J. [1 ]
Martinez, Ariel F. [1 ]
Abe, Yu [1 ]
Kruszka, Paul [1 ]
Weiss, Karin [1 ]
Everson, Joshua L. [2 ]
Bataller, Ramon [3 ]
Kleiner, David E. [4 ]
Ward, Jerrold M. [5 ]
Sulik, Kathleen K. [6 ,7 ,8 ]
Lipinski, Robert J. [2 ]
Solomon, Benjamin D. [1 ,9 ,10 ,11 ,12 ]
Muenke, Maximilian [1 ]
机构
[1] NHGRI, NIH, 35 Convent Dr,Room 1B203, Bethesda, MD 20892 USA
[2] Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA
[3] Univ N Carolina, Div Gastroenterol & Hepatol, Chapel Hill, NC USA
[4] NCI, Pathol Lab, Bldg 10, Bethesda, MD 20892 USA
[5] GlobalVet Pathol, Montgomery Village, MD USA
[6] Univ N Carolina, Carolina Inst Dev Disabil, Chapel Hill, NC USA
[7] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA
[8] Univ N Carolina, Bowles Ctr Alcohol Studies, Chapel Hill, NC USA
[9] Inova Translat Med Inst, Div Med Genom, Falls Church, VA USA
[10] Inova Childrens Hosp, Dept Pediat, Falls Church, VA USA
[11] Virginia Commonwealth Univ, Sch Med, Falls Church, VA USA
[12] GeneDx, Gaithersburg, MD USA
关键词
Non-alcoholic fatty liver disease; NAFLD; Metabolic disease; Hedgehog; SHH; GLI2; NASH; Liver fibrosis; Cirrhosis; Hepatocellular carcinoma; Holoprosencephaly; HPE; POTENTIAL THERAPEUTIC TARGETS; CHOLINE-DEFICIENT DIET; HEPATOCELLULAR-CARCINOMA; PEROXISOME-PROLIFERATOR; METABOLIC SYNDROME; SONIC-HEDGEHOG; IN-VITRO; DISEASE; NAFLD; MICE;
D O I
10.1016/j.jhep.2017.06.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease. Activation of hedgehog (Hh) signaling has been implicated in the progression of NAFLD and proposed as a therapeutic target; however, the effects of Hh signaling inhibition have not been studied in humans with germline mutations that affect this pathway. Methods: Patients with holoprosencephaly (HPE), a disorder associated with germline mutations disrupting Sonic hedgehog (SHH) signaling, were clinically evaluated for NAFLD. A combined mouse model of Hh signaling attenuation (Gli2 heterozygous null: Gli2(+/-)) and diet-induced NAFLD was used to examine aspects of NAFLD and hepatic gene expression profiles, including molecular markers of hepatic fibrosis and inflammation. Results: Patients with HPE had a higher prevalence of liver steatosis compared to the general population, independent of obesity. Exposure of Gli2(+/-) mice to fatty liver-inducing diets resulted in increased liver steatosis compared to wild-type mice. Similar to humans, this effect was independent of obesity in the mutant mice and was associated with decreased expression of pro-fibrotic and pro-inflammatory genes, and increased expression of PPAR gamma, a potent anti-fibrogenic and anti-inflammatory regulator. Interestingly, tumor suppressors p53 and p16INK4 were found to be downregulated in the Gli2(+/-) mice exposed to a high-fat diet. Conclusions: Our results indicate that germline mutations disrupting Hh signaling promotes liver steatosis, independent of obesity, with reduced fibrosis. While Hh signaling inhibition has been associated with a better NAFLD prognosis, further studies are required to evaluate the long-term effects of mutations affecting this pathway. Lay summary: Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat deposition in the liver predominantly due to high-calorie intake and a sedentary lifestyle. NAFLD progression is usually accompanied by the activation of Sonic hedgehog (SHH) pathway leading to fibrous buildup (scar tissue) and inflammation of the liver tissue. For the first time patients with holoprosencephaly, a disease caused by SHH signaling mutations, are shown to have increased liver steatosis independent of obesity. This observation was recapitulated in a mouse model of attenuated SHH signaling that also showed increased liver steatosis but with decreased fibrosis and inflammation. While SHH inhibition is associated with a good NAFLD prognosis, this increase in liver fat accumulation in the context of SHH signaling inhibition must be studied prospectively to evaluate its long-term effects, especially in individuals with Western-type dietary habits. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.
引用
收藏
页码:809 / 817
页数:9
相关论文
共 50 条
  • [21] Germline Wnt pathway alterations predispose to colorectal hyperplastic polyposis
    Quintana, Isabel
    Terradas, Mariona
    Mur, Pilar
    Aiza, Gemma
    Navarro, Matilde
    Pinol, Virginia
    Brunet, Joan
    Capella, Gabriel
    Valle, Laura
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 403 - 404
  • [22] Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
    Popova, Tatiana
    Hebert, Lucie
    Jacquemin, Virginie
    Gad, Sophie
    Caux-Moncoutier, Virginie
    Dubois-d'Enghien, Catherine
    Richaudeau, Benedicte
    Renaudin, Xavier
    Sellers, Jason
    Nicolas, Andre
    Sastre-Garau, Xavier
    Desjardins, Laurence
    Gyapay, Gabor
    Raynal, Virginie
    Sinilnikova, Olga M.
    Andrieu, Nadine
    Manie, Elodie
    de Pauw, Antoine
    Gesta, Paul
    Bonadona, Valerie
    Maugard, Christine M.
    Penet, Clotilde
    Avril, Marie-Francoise
    Barillot, Emmanuel
    Cabaret, Odile
    Delattre, Olivier
    Richard, Stephane
    Caron, Olivier
    Benfodda, Meriem
    Hu, Hui-Han
    Soufir, Nadem
    Bressac-de Paillerets, Brigitte
    Stoppa-Lyonnet, Dominique
    Stern, Marc-Henri
    AMERICAN JOURNAL OF HUMAN GENETICS, 2013, 92 (06) : 974 - 980
  • [23] Germline mutations in BAP1 predispose to melanocytic nevi and melanoma
    Wiesner, Thomas
    Obenauf, Anna
    Murali, Rajmohan
    Fried, Isabella
    Griewank, Klaus
    Ulz, Peter
    Windpassinger, Christian
    Loy, Shea
    Wackernagel, Werner
    Wolf, Ingrid
    Becker, Juergen
    Viale, Agnes
    Lash, Alex
    Pirun, Mono
    Socci, Nick
    Ruetten, Arno
    Palmedo, Gabrielle
    Ott, Arthur
    Abramson, David
    Offit, Kenneth
    Cerroni, Lorenzo
    Kutzner, Heinz
    Bastian, Boris
    Speicher, Michael
    CANCER RESEARCH, 2011, 71
  • [24] Germline Mutations of Centrobin Gene Likely Predispose Patients to Pancreatic Cancer
    Rubinstein, W. S.
    Zou, C.
    Koneru, R. H.
    Vogel, K.
    Wang, V.
    Kaul, K.
    Brand, R. E.
    Gao, Q.
    PANCREAS, 2010, 39 (08) : 1343 - 1343
  • [25] Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer
    S Bevan
    S M Edwards
    A Ardern Jones
    A Dowe
    C Southgate
    D Dearnaley
    D F Easton
    R S Houlston
    R Eeles
    Prostate Cancer and Prostatic Diseases, 2003, 6 : 12 - 14
  • [26] Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer
    Bevan, S
    Edwards, SM
    Jones, AA
    Dowe, A
    Southgate, C
    Dearnaley, D
    Easton, DF
    Houlston, RS
    Eeles, RA
    PROSTATE CANCER AND PROSTATIC DISEASES, 2003, 6 (01) : 12 - 14
  • [27] Keratin mutations predispose to cryptogenic liver diseases
    Marceau, N
    JOURNAL OF HEPATOLOGY, 2002, 36 (05) : 710 - 711
  • [28] HEDGEHOG PATHWAY ACTIVATION AND PATHOGENESIS OF CIRRHOSIS IN ALCOHOLIC AND NONALCOHOLIC FATTY LIVER DISEASE
    Diehl, A. M.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (08) : 59A - 59A
  • [29] Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis
    Jenkins, Zandra A.
    van Kogelenberg, Margriet
    Morgan, Tim
    Jeffs, Aaron
    Fukuzawa, Ryuji
    Pearl, Esther
    Thaller, Christina
    Hing, Anne V.
    Porteous, Mary E.
    Garcia-Minaur, Sixto
    Bohring, Axel
    Lacombe, Didier
    Stewart, Fiona
    Fiskerstrand, Torunn
    Bindoff, Laurence
    Berland, Siren
    Ades, Lesley C.
    Tchan, Michel
    David, Albert
    Wilson, Louise C.
    Hennekam, Raoul C. M.
    Donnai, Dian
    Mansour, Sahar
    Cormier-Daire, Valerie
    Robertson, Stephen P.
    NATURE GENETICS, 2009, 41 (01) : 95 - 100
  • [30] Germline mutations in Dok1 do not predispose to chronic lymphocytic leukemia
    Sellick, GS
    Coleman, RJ
    Talaban, R
    Fleischmann, C
    Rudd, MF
    Allinson, R
    Catovsky, D
    Houlston, RS
    LEUKEMIA RESEARCH, 2005, 29 (01) : 59 - 61